(Q34204360)

31 July 2017

1 reference

title

Latanoprost : an update of its use in glaucoma and ocular hypertension (English)

1 reference

31 July 2017

1 reference

1 reference

1

Caroline M Perry

1 reference

31 July 2017

Jane K McGavin

2

1 reference

31 July 2017

Christine R Culy

series ordinal

3

1 reference

31 July 2017

Tim Ibbotson

series ordinal

4

1 reference

31 July 2017

1 January 2003

1 reference

31 July 2017

1 reference

31 July 2017

20

1 reference

31 July 2017

8

1 reference

31 July 2017

597-630

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-200320080-00005

31 July 2017

0 references

cites work

Migraine headache associated with latanoprost

1 reference

12 December 2020

Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost

1 reference

12 December 2020

Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study

1 reference

12 December 2020

Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome

1 reference

12 December 2020

Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye

1 reference

12 December 2020

Latanoprost: experience of 2-year treatment in Scandinavia.

1 reference

12 December 2020

Latanoprost. Two years' experience of its use in the United Kingdom. Latanoprost Study Group.

1 reference

12 December 2020

Additive IOP-reducing effect of latanoprost in patients insufficiently controlled on timolol

1 reference

12 December 2020

Comparison of the intraocular pressure lowering effect of latanoprost and a fixed combination of timolol-pilocarpine eye drops in patients insufficiently controlled with beta adrenergic antagonists. French Latanoprost Study Group, and the Swedish La

1 reference

12 December 2020

Latanoprost 0.005%: evaluation of its effect on accommodative capacity

1 reference

12 December 2020

The pros and cons of different prostanoids in the medical management of glaucoma

1 reference

12 December 2020

Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol

1 reference

12 December 2020

Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group

1 reference

12 December 2020

The fine structure of an iridectomy specimen from a patient with latanoprost-induced eye color change

1 reference

12 December 2020

PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers

1 reference

12 December 2020

Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure

1 reference

12 December 2020

Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgus monkeys

1 reference

12 December 2020

Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study

1 reference

12 December 2020

Ultrasound biomicroscopic study of ciliary body thickness after topical application of pharmacologic agents

1 reference

12 December 2020

A comparative study of the effects of timolol and latanoprost on blood flow velocity of the retrobulbar vessels.

1 reference

12 December 2020

Clinical dose-regimen studies with latanoprost, a new ocular hypotensive PGF2 alpha analogue.

1 reference

12 December 2020

Effects of latanoprost and dipivefrin, alone or combined, on intraocular pressure and on blood-aqueous barrier permeability

1 reference

12 December 2020

Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy.

1 reference

12 December 2020

Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects

1 reference

12 December 2020

The effect of once-daily latanoprost on intraocular pressure and pulsatile ocular blood flow in normal tension glaucoma.

1 reference

12 December 2020

Visually significant cystoid macular edema in pseudophakic and aphakic patients with glaucoma receiving latanoprost

1 reference

12 December 2020

Acute primary angle-closure: long-term intraocular pressure outcome in Asian eyes

1 reference

12 December 2020

Comparison of the additive intraocular pressure-lowering effect of latanoprost and dorzolamide when added to timolol in patients with open-angle glaucoma or ocular hypertension: a randomized, open-label, multicenter study in Greece

1 reference

12 December 2020

Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study Groups.

1 reference

12 December 2020

Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells

1 reference

12 December 2020

Effects of latanoprost and timolol-XE on hydrodynamics in the normal eye

1 reference

12 December 2020

Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey

1 reference

12 December 2020

Cystoid macular edema associated with the use of latanoprost

1 reference

12 December 2020

Induction of c-fos by prostaglandin F2 alpha in human ciliary smooth muscle cells.

1 reference

12 December 2020

Effect of prostaglandins on cyclic AMP production in cultured human ciliary muscle cells

1 reference

12 December 2020

The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes

1 reference

12 December 2020

Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes

1 reference

12 December 2020

Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.

1 reference

12 December 2020

Intraocular pressure-reducing effect of PhXA41 in ocular hypertension. Comparison of dose regimens

1 reference

12 December 2020

The prevalence of glaucoma among Eskimos of northwest Alaska

1 reference

12 December 2020

Localization of the prostaglandin F2 alpha receptor messenger RNA and protein in the cynomolgus monkey eye

1 reference

12 December 2020

Antiglaucoma medications: a review of safety and tolerability issues related to their use.

1 reference

12 December 2020

Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension

1 reference

12 December 2020

Maintained intraocular pressure reduction with once-a-day application of a new prostaglandin F2 alpha analogue (PhXA41). An in-hospital, placebo-controlled study

1 reference

12 December 2020

Effect of latanoprost on intraocular pressure in steroid-induced glaucoma

1 reference

12 December 2020

Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension

1 reference

12 December 2020

Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma

1 reference

12 December 2020

Prevalence of blindness and cataract surgery in Shunyi County, China.

1 reference

12 December 2020

Matrix metalloproteinases

1 reference

12 December 2020

1 reference

12 December 2020

A comparison of the fixed combination of latanoprost and timolol with its individual components

1 reference

12 December 2020

Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.

1 reference

12 December 2020

Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost

1 reference

12 December 2020

Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients

1 reference

12 December 2020

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension

1 reference

12 December 2020

Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?

1 reference

12 December 2020

A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects

1 reference

12 December 2020

Evaluation and comparison between the effects on intraocular pressure and retinal blood flow of two antiglaucomatous drugs administered in monotherapy: brimonidine and latanoprost. Preliminary results

1 reference

12 December 2020

Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group

1 reference

12 December 2020

Acute effect of latanoprost on pulsatile ocular blood flow in normal eyes

1 reference

12 December 2020

Flow of aqueous humor in humans [The Friedenwald Lecture]

1 reference

12 December 2020

Prostaglandin F2 alpha and its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species

1 reference

12 December 2020

Pharmacological therapy for glaucoma: a review

1 reference

12 December 2020

Glaucoma in China: how big is the problem?

1 reference

12 December 2020

Vascular aspects in the pathophysiology of glaucomatous optic neuropathy.

1 reference

12 December 2020

Therapeutic potential of prostaglandin analogues in glaucoma

1 reference

12 December 2020

A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension

1 reference

12 December 2020

Three-month comparison of brimonidine and latanoprost as adjunctive therapy in glaucoma and ocular hypertension patients uncontrolled on beta-blockers: tolerance and peak intraocular pressure lowering

1 reference

12 December 2020

Discontinuation rates of topical glaucoma medications in a managed care population

1 reference

12 December 2020

Ocular and systemic pharmacokinetics of latanoprost in humans

1 reference

12 December 2020

Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells

1 reference

12 December 2020

Latanoprost 0.005% in POAG: effects on IOP and ocular blood flow

1 reference

12 December 2020

Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma

1 reference

12 December 2020

Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension

1 reference

12 December 2020

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

1 reference

12 December 2020

Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension

1 reference

12 December 2020

Comparison of the effect of latanoprost 0.005% and timolol 0.5% on the calculated ocular perfusion pressure in patients with normal-tension glaucoma

1 reference

12 December 2020

A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group

1 reference

12 December 2020

Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure

1 reference

12 December 2020

Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma

1 reference

12 December 2020

Latanoprost for uncontrolled glaucoma in a compassionate case protocol

1 reference

12 December 2020

Additive effect of latanoprost and dorzolamide in patients with elevated intraocular pressure.

1 reference

12 December 2020

Additive effect of latanoprost to the combination of timolol and dorzolamide.

1 reference

12 December 2020

Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients

1 reference

12 December 2020

Adverse effects of latanoprost on patients with medically resistant glaucoma

1 reference

12 December 2020

Effect of prostaglandins A(2), E(1), F(2 alpha)and latanoprost on cultured human iridal melanocytes

1 reference

12 December 2020

Correlation of asymmetric damage with asymmetric intraocular pressure in normal-tension glaucoma (low-tension glaucoma).

1 reference

12 December 2020

Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow.

1 reference

12 December 2020

Latanoprost-induced increase of tyrosinase transcription in iridial melanocytes

1 reference

12 December 2020

A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial

1 reference

12 December 2020

The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group

1 reference

12 December 2020

The color of the human eye: a review of morphologic correlates and of some conditions that affect iridial pigmentation

1 reference

12 December 2020

Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle

1 reference

12 December 2020

Incidence of acute primary angle-closure glaucoma in Singapore. An island-wide survey.

1 reference

12 December 2020

Potential mechanism for the additivity of pilocarpine and latanoprost

1 reference

12 December 2020

Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2 alpha-isopropyl ester analogues for glaucoma treatment

1 reference

12 December 2020

Interaction of PhXA41, a new prostaglandin analogue, with pilocarpine. A study on patients with elevated intraocular pressure

1 reference

12 December 2020

Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study

1 reference

12 December 2020

Intraocular pressure and glaucoma

1 reference

12 December 2020

Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: A double-masked, randomized, one-year study

1 reference

12 December 2020

Ultrabiomicroscopic study of the effects of brimonidine, apraclonidine, latanoprost and ibopamine on the chamber angle and ciliary body.

1 reference

12 December 2020

Additive effect of unoprostone and latanoprost in patients with elevated intraocular pressure

1 reference

12 December 2020

Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma.

1 reference

12 December 2020

Latanoprost accelerates disruption of the blood-aqueous barrier and the incidence of angiographic cystoid macular edema in early postoperative pseudophakias

1 reference

12 December 2020

Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro.

1 reference

12 December 2020

Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension

1 reference

12 December 2020

Herpes simplex virus dermatitis in patients using latanoprost

1 reference

12 December 2020

Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma

1 reference

12 December 2020

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

1 reference

12 December 2020

Cystoid macular edema associated with latanoprost use.

1 reference

12 December 2020

Comparison between isopropyl unoprostone and latanoprost by prostaglandin E(2)induction, affinity to prostaglandin transporter, and intraocular metabolism

1 reference

12 December 2020

Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes.

1 reference

12 December 2020

Latanoprost and periocular skin color changes.

1 reference

12 December 2020

Latanoprost and herpes simplex keratitis.

1 reference

12 December 2020

Prevalence of primary glaucoma in an urban south Indian population.

1 reference

12 December 2020

Drug points. Exacerbation of angina associated with latanoprost

1 reference

12 December 2020

The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy

1 reference

12 December 2020

The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%.

1 reference

12 December 2020

Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway

1 reference

12 December 2020

Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma

1 reference

12 December 2020

Hypertrichosis induced by latanoprost

1 reference

12 December 2020

Medical Management of Glaucoma

1 reference

12 December 2020

Systemic adverse effects associated with topically applied latanoprost

1 reference

12 December 2020

Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost

1 reference

12 December 2020

Additive ocular hypotensive effect of latanoprost and acetazolamide. A short-term study in patients with elevated intraocular pressure

1 reference

12 December 2020

Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data.

1 reference

12 December 2020

A comparison of treated and untreated glaucoma suspects

1 reference

12 December 2020

A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension

1 reference

12 December 2020

Effects of latanoprost and unoprostone when used alone or in combination for open-angle glaucoma

1 reference

12 December 2020

Efficacy and adverse effects of medications used in the treatment of glaucoma

1 reference

12 December 2020

A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma

1 reference

12 December 2020

Induction of tyrosinase gene transcription in human iris organ cultures exposed to latanoprost.

1 reference

12 December 2020

Effects on intraocular pressure and aqueous flow of various dose regimens of latanoprost in human eyes.

1 reference

12 December 2020

Shortterm “escape” and longterm “drift.”. The dissipation effects of the beta adrenergic blocking agents

1 reference

12 December 2020

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

1 reference

12 December 2020

Number of people with glaucoma worldwide

1 reference

12 December 2020

Additive intraocular pressure lowering effect of various medications with latanoprost

1 reference

12 December 2020

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

1 reference

12 December 2020

Synthesis pattern of matrix metalloproteinases (MMPs) and inhibitors (TIMPs) in human explant organ cultures after treatment with latanoprost and dexamethasone

1 reference

12 December 2020

Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes

1 reference

12 December 2020

Ocular complications of latanoprost in uveitic glaucoma: three case reports

1 reference

12 December 2020

Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study

1 reference

12 December 2020

The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension

1 reference

12 December 2020

The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

1 reference

12 December 2020

Latanoprost and cystoid macular oedema in a pseudophake

1 reference

12 December 2020

Additive effect of latanoprost, a prostaglandin F2 alpha analogue, and timolol in patients with elevated intraocular pressure

1 reference

12 December 2020

Latanoprost 0.005% and anterior segment uveitis

1 reference

12 December 2020

Herpes simplex dendritic keratitis after treatment with latanoprost for primary open angle glaucoma

1 reference

12 December 2020

Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension

1 reference

12 December 2020

Latanoprost and cystoid macular edema: is there a causal relation?

1 reference

12 December 2020

Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.

1 reference

12 December 2020

Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections

1 reference

12 December 2020

Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double-masked, long-term clinical trial

1 reference

12 December 2020

Efficacy and safety of latanoprost eye drops for glaucoma treatment: a 1-year study in Japan

1 reference

12 December 2020

Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation

1 reference

12 December 2020

Rates of discontinuation and change of glaucoma therapy in a managed care setting.

1 reference

12 December 2020

[An epidemiologic study of glaucoma in Shunyi County, Beijing]

1 reference

12 December 2020

Effects of exogenous prostaglandins on aqueous humor dynamics and blood-aqueous barrier function

1 reference

12 December 2020

Reduced intraocular pressure and increased ocular perfusion pressure in normal tension glaucoma: a review of short-term studies with three dose regimens of latanoprost treatment.

1 reference

12 December 2020

Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha

1 reference

12 December 2020

The mechanism of action of prostaglandins on uveoscleral outflow

1 reference

12 December 2020

Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines

1 reference

12 December 2020

Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans.

1 reference

12 December 2020

A randomized, comparative open-label study on the efficacy of latanoprost and timolol in steroid induced ocular hypertension after photorefractive keratectomy

1 reference

12 December 2020

Latanoprost-associated cystoid macular edema

1 reference

12 December 2020

Hypotensive efficacy in primary open-angle glaucoma and ocular hypertension: latanoprost in monotherapy vs timolol and dorzolamide in association

1 reference

12 December 2020

Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension

1 reference

12 December 2020

Prevalence of glaucoma. The Beaver Dam Eye Study.

1 reference

12 December 2020

Corneal toxicity associated with latanoprost

1 reference

12 December 2020

A comparison of the effects on intraocular pressure of latanoprost 0.005% and the fixed combination of dorzolamide 2% and timolol 0.5% in patients with open-angle glaucoma

1 reference

12 December 2020

Check for pregnancy before prescribing clomifene

1 reference

12 December 2020

Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States.

1 reference

12 December 2020

Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients

1 reference

12 December 2020

Anterior uveitis associated with latanoprost

1 reference

12 December 2020

Latanoprost exerts neuroprotective activity in vitro and in vivo

1 reference

12 December 2020

Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial

1 reference

12 December 2020

Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension

1 reference

12 December 2020

Effects of 0.005% latanoprost on optic nerve head and peripapillary retinal blood flow

1 reference

12 December 2020

10.2165/00002512-200320080-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference